Challenge to cancer gene patent fails in Australia

February 15, 2013

An Australian court Friday dismissed a challenge against the patenting of human genetic material in a landmark case which has devastated a cancer group that says it could stifle research.

The case hinged on whether a valid patent can be granted to cover naturally occurring , the building blocks of living organisms—in this case the so-called BRCA1.

Federal Court Justice John Nicholas rejected the argument that BRCA1, a genetic mutation associated with an increased risk of breast and in women, could not be patented because it was a naturally occurring substance.

He ruled instead in favour of the two medical research companies that hold the patent, US-based Myriad Genetics and Melbourne-based Genetic Technologies Ltd.

"There is no doubt that naturally occurring DNA and RNA as they exist inside the cells of the human body cannot be the subject of a valid patent," his judgement concluded. DNA and RNA are types of nucleic acid.

"However, the disputed claims do not cover naturally occurring DNA and RNA as they exist inside such cells.

"The disputed claims extend only to naturally occurring DNA and RNA which have been extracted from cells obtained from the human body and purged of other biological materials with which they were associated."

The decision is the first in the country to consider whether isolated DNA or can be patented and lawyers for Cancer Voices Australia, which brought the case, have argued it raises ethical issues about the commercialisation of the human body.

The judgement is a blow to the cancer campaigners, with the woman who brought the case, Yvonne D'Arcy, leaving the court in tears.

"To tell the truth I'm very disappointed," she told reporters. "We were doing this for future generations, and I'm just so disappointed."

Cancer Voices Australia also expressed its disappointment in losing the case which it said was for people with all diseases with .

"We think that is it very important that information about people's genes (and) genetic makeup be freely available to researchers, not only in Australia, but around the world," Cancer Voices' John Stubbs told the ABC.

Related Stories

Myriad can patent breast cancer genes: US court

July 30, 2011

A federal appeals court on Friday ruled in favor of Myriad Genetics after a legal battle over whether the US company could keep its patent on genes linked to an inherited form of breast cancer.

Map reveals cancer hotspots

February 22, 2012

(Medical Xpress) -- A new technique is helping researchers to pinpoint genetic information that contributes to cancer development.

High court throws out human gene patents

March 26, 2012

(AP) -- The Supreme Court on Monday threw out a lower court ruling allowing human genes to be patented, a topic of enormous interest to cancer researchers, patients and drug makers.

Recommended for you

Strange circular DNA may offer new way to detect cancers

July 30, 2015

Strange rings of DNA that exist outside chromosomes are distinct to the cell types that mistakenly produced them, researchers have discovered. The finding raises the tantalizing possibility that the rings could be used as ...

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

SDrapak
not rated yet Feb 15, 2013
The problem is that if you take away the financial reasons for companies to develop therapies, they have no reason to pursue them. Even the most well-intentioned company needs money or it will cease to exist. So there has to be a balance between encouraging research and patents that are used for greed rather than helping the general population.
That being said, there are always people and companies that will ignore patents and go ahead and do what they want anyway.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.